Lv2
150 积分 2020-04-04 加入
Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development
2天前
已完结
From 3-Tier to adaptive immunogenicity testing strategies: recommendations from the European Bioanalysis Forum
2天前
已完结
Examining pre-analytical factors for bioanalysis of protein therapeutics crossing the blood–brain barrier through receptor-mediated transcytosis
2天前
求助中
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
2天前
已完结
Divergent Paths, Convergent Goals: Institutional Experiments in Cell and Gene Therapy Regulation and Payment Between China and the United States
2天前
已完结
Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development
27天前
已关闭
Harmonizing immunogenicity for AAV and LNP/mRNA modalities: best-practice panels for binding, neutralizing, and cellular assays with pre-existing immunity controls
30天前
已完结
Strategy for streamlining antibody–drug conjugate pharmacokinetic assays
1个月前
已关闭
Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products
1个月前
已完结
Mitigation of pre-existing immunogenicity in ADA method development
2个月前
已关闭
皖公网安备34019202002308
